To systematically evaluate the efficacy and safety of Xiaoyao formula (XYF) as an adjuvant treatment of post-stroke depression (PSD) by conducting a meta-analysis.Methods:
Pubmed, Embase, Cochrane Library, CNKI, VIP, and Wanfang databases were searched up to May 2016. Randomized controlled trials investigating XYF plus antidepressants versus antidepressants alone for patients with PSD were considered.Results:
A total of 607 PSD patients were identified from 7 trials. Adjuvant treatment with XYF had additional benefits in terms of improved total response rates (risk ratio [RR] 1.21; 95% confidence interval [CI]: 1.12–1.30), reduced Hamilton's depressive scale (weighted mean difference [WMD] −5.21; 95% CI: −7.48 to −2.95), and decreased Scandinavian Stroke Scale (WMD −6.35; 95% CI: −8.27 to −4.43). No serious adverse events were observed in any of the included trials.Conclusions:
Adjuvant treatment with XYF appears to have additional benefits in the treatment of PSD, without increasing serious adverse events.